Jean-loup Demory

Lille, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera.

Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera.

Journal: Leukemia

Published: August 13, 2024

Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs.

Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs.

Journal: Blood advances

Published: January 31, 2022

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study.

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study.

Journal: Haematologica

Published: September 22, 2017

Microparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombocythemia.

Microparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombocythemia.

Journal: Haematologica

Published: June 02, 2016

Coherent manipulation of a solid-state artificial atom with few photons.

Coherent manipulation of a solid-state artificial atom with few photons.

Journal: Nature communications

Published: April 04, 2016

Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.

Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.

Journal: Haematologica

Published: October 02, 2014

Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups.

Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups.

Journal: British journal of haematology

Published: March 18, 2013

Improving survival trends in primary myelofibrosis: an international study.

Improving survival trends in primary myelofibrosis: an international study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 25, 2012

Showing 1-8 of 8

Last Updated: 09/26/2026